Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: PAL who wrote (698)	5/5/1998 1:16:00 PM
From: PK	Respond to of 2135

>> Chief Financial Officer Nelson Campbell said EntreMed >> is in talks with several other major pharmaceutical companies >> for a deal to develop endostatin. He declined to comment on >> possible partners or when a deal might be reached. With only 5.9M shares in float and 30M+ Volume yesterday, (assuming Buys outnumbered sells yesterday ) there can be a substantial short squeeze in an event of news about a partner for production. Cosidering the kind of attention ENMD has got, that might happen sooner then you think.